Loading...
Market
How many new clinical trials involving J&J's multiple myeloma drug combinations will be initiated by September 27, 2025?
2
Resolution / Starting Odds
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Clinical trial registries and Johnson & Johnson press releases
Story
Johnson & Johnson's ($JNJ) New Drug Combinations Show Promise in Multiple Myeloma Treatment
Sep 27, 2024, 12:05 PM
Johnson & Johnson's novel combinations of TALVEY® (talquetamab-tgvs) with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) show promising results in treating patients with relapsed or refractory multiple myeloma. The combinations suggest high response rates and durable responses, including in triple-class refractory patients and those with extramedullary disease. These findings indicate potential advancements in treatment options for this challenging condition. The results are significant for Johnson & Johnson ($JNJ) and its partners, including $GMAB.DC and $GMAB.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Yes • 50%
No • 50%
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
Less than 20% • 25%
20% to 25% • 25%
25% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-2 trials • 25%
3-5 trials • 25%
6-8 trials • 25%
More than 8 trials • 25%